Actuate Therapeutics reports positive Phase 2 pancreatic cancer data

Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialThe latest announcement is out from Actuate Therapeutics, Inc. ( (ACTU) ). On January 12, 2026, Actuate Therapeutics reported positive follow-up data from its fully enrolled randomized Phase 2 Actuate-1801 Part 3B trial, showing that elraglusib combined with gemcitabine/nab-paclitaxel significantly improved survival outcomes in first-line treatment of metastatic pancreatic ductal adenocarcinoma. The study, which enrolled 286 patients across 60 sites in six countries, met its primary endpoint with median overall survival of 10.1 months for the elraglusib/chemotherapy arm versus 7.2 months for chemotherapy alone, corresponding to a 38% reduction in risk of death, and showed notably higher 12- and 24-month survival rates as of data presented at ASCO GI on January 9, 2026. Safety and tolerability were broadly comparable between treatment arms with no new safety signals, while genomic and immunologic biomarker analyses suggested potential predictive markers and immune activation specific to the elraglusib combination. The data strengthen Actuate’s clinical case for elraglusib in metastatic pancreatic cancer and support its strategic positioning as a developer of novel targeted therapies in a setting with limited effective first-line options, with ongoing survivors on the elraglusib regimen underscoring the potential for durable benefit relative to standard care. The most recent analyst rating on (ACTU) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Actuate Therapeutics, Inc. stock, see the ACTU Stock Forecast page. More about Actuate Therapeutics, Inc. Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for high-impact, difficult-to-treat cancers by targeting glycogen synthase kinase-3 beta (GSK-3β). Its lead investigational drug, elraglusib, is designed to inhibit pathways that drive tumor growth, resistance to chemotherapy, and potentially modulate anti-tumor immunity, positioning the company in the oncology market focused on metastatic and hard-to-treat malignancies. Average Trading Volume: 73,185 Technical Sentiment Signal: Sell Current Market Cap: $146M Find detailed analytics on ACTU stock on TipRanks’ Stock Analysis page.